Your browser doesn't support javascript.
loading
[Effect of 2-phenylethyl-beta-glucopyranoside isolated from Huaizhong No. 1 Rehmannia glutinosa on hypoxic pulmonary hypertension by regulating PI3K/Akt/m TOR/HIF-1α pathway].
Zeng, Meng-Nan; Zhang, Yu-Han; Guo, Peng-Li; Zhang, Zi-Yu; Liu, Yan-Ling; Wang, Ru; Tie, Qi-Mei; Wang, Yuan-Yuan; Chang, Fang-Zhuo; Feng, Wei-Sheng; Zheng, Xiao-Ke.
Afiliação
  • Zeng MN; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & E
  • Zhang YH; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China.
  • Guo PL; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China.
  • Zhang ZY; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China.
  • Liu YL; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China.
  • Wang R; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China.
  • Tie QM; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China.
  • Wang YY; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China.
  • Chang FZ; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China.
  • Feng WS; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & E
  • Zheng XK; School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & E
Zhongguo Zhong Yao Za Zhi ; 49(14): 3857-3867, 2024 Jul.
Article em Zh | MEDLINE | ID: mdl-39099359
ABSTRACT
The study investigated the protective effect and mechanism of 2-phenylethyl-beta-glucopyranoside(Phe) from Huaizhong No.1 Rehmannia glutinosa on hypoxic pulmonary hypertension(PH), aiming to provide a theoretical basis for clinical treatment of PAH. Male C57BL/6N mice were randomly divided into normal group, model group, positive drug(bosentan, 100 mg·kg~(-1)) group, and low-and high-dose Phe groups(20 and 40 mg·kg~(-1)). Except for the normal group, all other groups were continuously subjected to model induction in a 10% hypoxic environment for 5 weeks, with oral administration for 14 days starting from the 3rd week. The cardiopulmonary function, right ventricular pressure, cough and asthma index, lung injury, cell apoptosis, oxidative stress-related indicators, immune cells, and phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)/mammalian target of rapamycin(mTOR)/hypoxic inducible factor 1α(HIF-1α) pathway-related proteins or mRNA levels were examined. Furthermore, hypoxia-induced pulmonary arterial smooth muscle cell(PASMC) were used to further explore the mechanism of Phe intervention in PH combined with PI3K ago-nist(740Y-P). The results showed that Phe significantly improved the cardiopulmonary function of mice with PH, decreased right ventricular pressure, cough and asthma index, and lung injury, reduced cell apoptosis, oxidative stress-related indicators, and nuclear levels of phosphorylated Akt(p-Akt) and phosphorylated mTOR(p-mTOR), inhibited the expression levels of HIF-1α and PI3K mRNA and proteins, and maintained the immune cell homeostasis in mice. Further mechanistic studies revealed that Phe significantly reduced the viability and migration ability of hypoxia-induced PASMC, decreased the expression of HIF-1α and PI3K proteins and nuc-lear levels of p-Akt and p-mTOR, and this effect was blocked by 740Y-P. Therefore, it is inferred that Phe may exert anti-PH effects by alleviating the imbalance of oxidative stress and apoptosis in lung tissues and regulating immune levels, and its mechanism may be related to the regulation of the PI3K/Akt/mTOR/HIF-1α pathway. This study is expected to provide drug references and research ideas for the treatment of PH.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfatidilinositol 3-Quinases / Rehmannia / Proteínas Proto-Oncogênicas c-akt / Subunidade alfa do Fator 1 Induzível por Hipóxia / Serina-Treonina Quinases TOR / Glucosídeos / Hipertensão Pulmonar / Hipóxia / Camundongos Endogâmicos C57BL Limite: Animals / Humans / Male Idioma: Zh Revista: Zhongguo Zhong Yao Za Zhi Assunto da revista: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfatidilinositol 3-Quinases / Rehmannia / Proteínas Proto-Oncogênicas c-akt / Subunidade alfa do Fator 1 Induzível por Hipóxia / Serina-Treonina Quinases TOR / Glucosídeos / Hipertensão Pulmonar / Hipóxia / Camundongos Endogâmicos C57BL Limite: Animals / Humans / Male Idioma: Zh Revista: Zhongguo Zhong Yao Za Zhi Assunto da revista: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Ano de publicação: 2024 Tipo de documento: Article